Sign up to save your podcasts
Or
Share Why Biopharma Needs to Tell Better Stories on Novel Drugs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Why Biopharma Needs to Tell Better Stories on Novel Drugs
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.
View all episodes
By RBC Capital Markets
5
1212 ratings
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry.
More shows like Pathfinders in Biopharma
View all
Motley Fool Money
3,221 Listeners
WSJ Your Money Briefing
1,720 Listeners
Exchanges
973 Listeners
Odd Lots
1,898 Listeners
WSJ Tech News Briefing
1,640 Listeners
a16z Podcast
1,101 Listeners
The Long Run with Luke Timmerman
123 Listeners
The Readout Loud
324 Listeners
Wall Street Breakfast
1,041 Listeners
Thoughts on the Market
1,307 Listeners
The Journal.
6,076 Listeners
BioCentury This Week
34 Listeners
RBC's Markets in Motion
40 Listeners
Biotech Hangout
19 Listeners
Industries in Motion
10 Listeners
Powering Sustainable Ideas
0 Listeners
The Markets
74 Listeners
Strategic Alternatives
18 Listeners
The Top Line
15 Listeners
Macro Minutes
3 Listeners